• Pivotal clinical study data published in Clinical Gastroenterology and Hepatology. View the published study here.
• All study endpoints were achieved, with findings presented recently at major U.S. and European gastroenterology conferences.
• Data will support a U.S. FDA regulatory submission for an initial indication to evaluate whole and regional gut transit to assess common gastrointestinal motility disorders.

MELBOURNE, AUSTRALIA & SAN DIEGO, USA, 4 March 2025:

Atmo Biosciences, the innovator behind the ingestible gas-sensing capsule for gut health, today announced the publication of pivotal clinical study data in Clinical Gastroenterology and Hepatology. The study validates the Atmo Capsule for assessing whole and regional gastrointestinal transit times to assist with the diagnosis of highly prevalent motility disorders such as gastroparesis (delayed emptying from the stomach) and slow transit constipation.

More than 200 subjects from 12 trial sites in the U.S. and Australia ingested the Atmo Gas Capsule and a predicate device, the Wireless Motility Capsule, to test the comparative ability of Atmo to assess the primary endpoints of gastric emptying time (emptying from the stomach) and colonic transit time (transit time in the large bowel) to assist with diagnosis of gastroparesis and slow transit constipation.

All study endpoints were met and the findings were subsequently presented at major gastroenterology conferences in late 2024, including the United European Gastroenterology Week (UEGW), the American College of Gastroenterology (ACG) meeting, and the Federation of Neurogastroenterology and Motility Meeting (FNM).

Principal investigator Dr. Braden Kuo, of Massachusetts General Hospital, commented, “The comparative study data shows that the Atmo Gas Capsule correlated well with the other technology on assessments of gastric emptying time and colonic transit time. These results demonstrate that the Atmo Capsule is a clinically useful method for evaluating gastrointestinal transit.”

Mal Hebblewhite, Atmo CEO, said ” The publication of our pivotal clinical study data is a significant milestone for Atmo, marking the culmination of years of R&D, clinical collaboration, and a steadfast commitment to transforming patient care. We are thrilled to share these findings with the global medical community, bringing us one step closer to making the technology available to clinicians to improve outcomes for those who need it most.”

The results from the pivotal study will support a 510(k) submission to the U.S. Food and Drug Administration (FDA) seeking regulatory clearance in an initial indication for the use of the Atmo Capsule to assess gastrointestinal motility disorders.

About Atmo Biosciences:

Atmo Biosciences is a digital health business commercializing an ingestible capsule that provides insight into gut health. Atmo’s gas-sensing capsule measures whole and regional gut transit times to aid gastroenterologists in diagnosing gut motility disorders. Atmo strives to improve the quality of life for the many sufferers of common and debilitating gastrointestinal disorders and diseases, providing clinicians and researchers with tools that deliver actionable insights regarding gastrointestinal dysfunction. The gas-sensing capsule is currently being used in research applications in multiple clinical trials around the world. www.atmobiosciences.com

The Atmo Gas Capsule System is pending FDA 510(k) clearance and is not available for sale. The Atmo Gas Capsule System is an investigational device exclusively for use in clinical research.